Treatment of central giant cell granuloma of the jaws with intralesional denosumab: initial report.

Central giant cell granuloma (CGCG) is a rare, benign but aggressive osteolytic lesion affecting the jaws. Traditional surgical management, while effective, often results in functional and aesthetic deficits due to the resection of bone and soft tissue. Medical treatment with corticosteroids, subcutaneous calcitonin, or intravenous bisphosphonates has demonstrated variable success. Recent studies have shown that denosumab, a monoclonal antibody targeting RANKL (receptor activator of nuclear factor kappa-B ligand), can inhibit osteoclast activity, thus providing a novel treatment approach. This study reports the outcomes of eight patients with CGCG treated with intralesional denosumab injections (mean follow-up 36 months, range 12-61 months), highlighting its efficacy in reducing the size of the lesion, increasing bone density, and avoiding the need for surgery in most of the cases.